Active-site studies of neurohypophyseal hormones: Comparison of oxytocin and arginine-vasopressin with analogues containing 4-D-glutamine

Victor J Hruby, Henry I. Mosberg, Venkatappa Viswanatha

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Previous studies have indicated that oxytocin at the uterine smooth-muscle receptor and vasopressin at the mammalian antidiuretic receptor utilize different structural and conformational properties to produce their biological effects. In both cases, however, the Gln4 residue has been proposed to be of primary importance for receptor recognition (binding) but not critical for biological activity (transduction). On the basis of these considerations, it would be predicted that [D-Gln4] oxytocin and [D-Gln4,Arg8]vasopressin would be weak but full agonists at the uterine and antidiuretic receptors, respectively. We have synthesized and purified the two D-Gln4 analogues and examined their pharmacological activities in several assay systems for these hormones. In agreement with the predictions, [D-Gln4]oxytocin and [D-Gln4,Arg8]vasopressin have greatly reduced potency at the in vitro uterine and in vivo antidiuretic assay systems, respectively, and both appear to be full agonists in these assays. However, the effects are quantitatively different, with [D-Gln4] oxytocin possessing 3.3 ± 0.2 units/mg of uterotonic activity (1/170 the potency of oxytocin) and [D-Gln4,Arg8]vasopressin possessing only 0.45 ± 0.01 unit/mg (1/1100 the potency of arginine vasopressin) of antidiuretic activity. Based on carbon-13 nuclear magnetic resonance spectral data, both [D-Gln4]oxytocin and [D-Gln4,Arg8]vasopressin have very similar conformations to oxytocin and arginine-vasopressin, respectively. Interestingly [D-Gln4]oxytocin has much more reduced biological activities relative to the native hormone in the avian vasodepressor (∼0.04 unit/mg, ∼1/12000 that of oxytocin) and milk-ejecting (0.09 ± 0.02 unit/mg, ∼1/4500 that of oxytocin) assays and is a weak partial agonist in the pressor assay. [D-Gln4,Arg8]vasopressin is a weak full agonist in the pressor assay (0.260 ± 0.004 unit/mg, 1/1900 that of arginine-vasopressin) and also has weak uterotonic (∼0.11 unit/mg) and avian vasodepressor (0.10 unit/mg) activities.

Original languageEnglish (US)
Pages (from-to)837-841
Number of pages5
JournalJournal of the American Chemical Society
Volume104
Issue number3
StatePublished - 1982

Fingerprint

Posterior Pituitary Hormones
Arginine
Arginine Vasopressin
Hormones
Oxytocin
Glutamine
Assays
Catalytic Domain
Vasopressins
Bioactivity
Muscle
Conformations
Vasopressin Receptors
Nuclear magnetic resonance
Myometrium
Carbon
Smooth Muscle
Milk
Magnetic Resonance Spectroscopy
Pharmacology

ASJC Scopus subject areas

  • Chemistry(all)

Cite this

Active-site studies of neurohypophyseal hormones : Comparison of oxytocin and arginine-vasopressin with analogues containing 4-D-glutamine. / Hruby, Victor J; Mosberg, Henry I.; Viswanatha, Venkatappa.

In: Journal of the American Chemical Society, Vol. 104, No. 3, 1982, p. 837-841.

Research output: Contribution to journalArticle

@article{e9a004c1efaf441994c4097d19fe3253,
title = "Active-site studies of neurohypophyseal hormones: Comparison of oxytocin and arginine-vasopressin with analogues containing 4-D-glutamine",
abstract = "Previous studies have indicated that oxytocin at the uterine smooth-muscle receptor and vasopressin at the mammalian antidiuretic receptor utilize different structural and conformational properties to produce their biological effects. In both cases, however, the Gln4 residue has been proposed to be of primary importance for receptor recognition (binding) but not critical for biological activity (transduction). On the basis of these considerations, it would be predicted that [D-Gln4] oxytocin and [D-Gln4,Arg8]vasopressin would be weak but full agonists at the uterine and antidiuretic receptors, respectively. We have synthesized and purified the two D-Gln4 analogues and examined their pharmacological activities in several assay systems for these hormones. In agreement with the predictions, [D-Gln4]oxytocin and [D-Gln4,Arg8]vasopressin have greatly reduced potency at the in vitro uterine and in vivo antidiuretic assay systems, respectively, and both appear to be full agonists in these assays. However, the effects are quantitatively different, with [D-Gln4] oxytocin possessing 3.3 ± 0.2 units/mg of uterotonic activity (1/170 the potency of oxytocin) and [D-Gln4,Arg8]vasopressin possessing only 0.45 ± 0.01 unit/mg (1/1100 the potency of arginine vasopressin) of antidiuretic activity. Based on carbon-13 nuclear magnetic resonance spectral data, both [D-Gln4]oxytocin and [D-Gln4,Arg8]vasopressin have very similar conformations to oxytocin and arginine-vasopressin, respectively. Interestingly [D-Gln4]oxytocin has much more reduced biological activities relative to the native hormone in the avian vasodepressor (∼0.04 unit/mg, ∼1/12000 that of oxytocin) and milk-ejecting (0.09 ± 0.02 unit/mg, ∼1/4500 that of oxytocin) assays and is a weak partial agonist in the pressor assay. [D-Gln4,Arg8]vasopressin is a weak full agonist in the pressor assay (0.260 ± 0.004 unit/mg, 1/1900 that of arginine-vasopressin) and also has weak uterotonic (∼0.11 unit/mg) and avian vasodepressor (0.10 unit/mg) activities.",
author = "Hruby, {Victor J} and Mosberg, {Henry I.} and Venkatappa Viswanatha",
year = "1982",
language = "English (US)",
volume = "104",
pages = "837--841",
journal = "Journal of the American Chemical Society",
issn = "0002-7863",
publisher = "American Chemical Society",
number = "3",

}

TY - JOUR

T1 - Active-site studies of neurohypophyseal hormones

T2 - Comparison of oxytocin and arginine-vasopressin with analogues containing 4-D-glutamine

AU - Hruby, Victor J

AU - Mosberg, Henry I.

AU - Viswanatha, Venkatappa

PY - 1982

Y1 - 1982

N2 - Previous studies have indicated that oxytocin at the uterine smooth-muscle receptor and vasopressin at the mammalian antidiuretic receptor utilize different structural and conformational properties to produce their biological effects. In both cases, however, the Gln4 residue has been proposed to be of primary importance for receptor recognition (binding) but not critical for biological activity (transduction). On the basis of these considerations, it would be predicted that [D-Gln4] oxytocin and [D-Gln4,Arg8]vasopressin would be weak but full agonists at the uterine and antidiuretic receptors, respectively. We have synthesized and purified the two D-Gln4 analogues and examined their pharmacological activities in several assay systems for these hormones. In agreement with the predictions, [D-Gln4]oxytocin and [D-Gln4,Arg8]vasopressin have greatly reduced potency at the in vitro uterine and in vivo antidiuretic assay systems, respectively, and both appear to be full agonists in these assays. However, the effects are quantitatively different, with [D-Gln4] oxytocin possessing 3.3 ± 0.2 units/mg of uterotonic activity (1/170 the potency of oxytocin) and [D-Gln4,Arg8]vasopressin possessing only 0.45 ± 0.01 unit/mg (1/1100 the potency of arginine vasopressin) of antidiuretic activity. Based on carbon-13 nuclear magnetic resonance spectral data, both [D-Gln4]oxytocin and [D-Gln4,Arg8]vasopressin have very similar conformations to oxytocin and arginine-vasopressin, respectively. Interestingly [D-Gln4]oxytocin has much more reduced biological activities relative to the native hormone in the avian vasodepressor (∼0.04 unit/mg, ∼1/12000 that of oxytocin) and milk-ejecting (0.09 ± 0.02 unit/mg, ∼1/4500 that of oxytocin) assays and is a weak partial agonist in the pressor assay. [D-Gln4,Arg8]vasopressin is a weak full agonist in the pressor assay (0.260 ± 0.004 unit/mg, 1/1900 that of arginine-vasopressin) and also has weak uterotonic (∼0.11 unit/mg) and avian vasodepressor (0.10 unit/mg) activities.

AB - Previous studies have indicated that oxytocin at the uterine smooth-muscle receptor and vasopressin at the mammalian antidiuretic receptor utilize different structural and conformational properties to produce their biological effects. In both cases, however, the Gln4 residue has been proposed to be of primary importance for receptor recognition (binding) but not critical for biological activity (transduction). On the basis of these considerations, it would be predicted that [D-Gln4] oxytocin and [D-Gln4,Arg8]vasopressin would be weak but full agonists at the uterine and antidiuretic receptors, respectively. We have synthesized and purified the two D-Gln4 analogues and examined their pharmacological activities in several assay systems for these hormones. In agreement with the predictions, [D-Gln4]oxytocin and [D-Gln4,Arg8]vasopressin have greatly reduced potency at the in vitro uterine and in vivo antidiuretic assay systems, respectively, and both appear to be full agonists in these assays. However, the effects are quantitatively different, with [D-Gln4] oxytocin possessing 3.3 ± 0.2 units/mg of uterotonic activity (1/170 the potency of oxytocin) and [D-Gln4,Arg8]vasopressin possessing only 0.45 ± 0.01 unit/mg (1/1100 the potency of arginine vasopressin) of antidiuretic activity. Based on carbon-13 nuclear magnetic resonance spectral data, both [D-Gln4]oxytocin and [D-Gln4,Arg8]vasopressin have very similar conformations to oxytocin and arginine-vasopressin, respectively. Interestingly [D-Gln4]oxytocin has much more reduced biological activities relative to the native hormone in the avian vasodepressor (∼0.04 unit/mg, ∼1/12000 that of oxytocin) and milk-ejecting (0.09 ± 0.02 unit/mg, ∼1/4500 that of oxytocin) assays and is a weak partial agonist in the pressor assay. [D-Gln4,Arg8]vasopressin is a weak full agonist in the pressor assay (0.260 ± 0.004 unit/mg, 1/1900 that of arginine-vasopressin) and also has weak uterotonic (∼0.11 unit/mg) and avian vasodepressor (0.10 unit/mg) activities.

UR - http://www.scopus.com/inward/record.url?scp=0020054178&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020054178&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0020054178

VL - 104

SP - 837

EP - 841

JO - Journal of the American Chemical Society

JF - Journal of the American Chemical Society

SN - 0002-7863

IS - 3

ER -